NASDAQ:CMMB Chemomab Therapeutics (CMMB) Stock Price, News & Analysis $0.98 +0.01 (+1.03%) Closing price 08/6/2025 03:55 PM EasternExtended Trading$2.50 +1.52 (+155.10%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Chemomab Therapeutics Stock (NASDAQ:CMMB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Chemomab Therapeutics alerts:Sign Up Key Stats Today's Range$0.97▼$1.0050-Day Range$0.97▼$1.3652-Week Range$0.87▼$2.55Volume26,904 shsAverage Volume134,466 shsMarket Capitalization$18.48 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingBuy Company Overview Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel. Read More Chemomab Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreCMMB MarketRank™: Chemomab Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 1248th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingChemomab Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageChemomab Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Chemomab Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Chemomab Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chemomab Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chemomab Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChemomab Therapeutics has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Chemomab Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.03% of the float of Chemomab Therapeutics has been sold short.Short Interest Ratio / Days to CoverChemomab Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemomab Therapeutics has recently increased by 9.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChemomab Therapeutics does not currently pay a dividend.Dividend GrowthChemomab Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.03% of the float of Chemomab Therapeutics has been sold short.Short Interest Ratio / Days to CoverChemomab Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemomab Therapeutics has recently increased by 9.30%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Chemomab Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for CMMB on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Chemomab Therapeutics' insider trading history. Receive CMMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CMMB Stock News HeadlinesComparing Chemomab Therapeutics (NASDAQ:CMMB) & Mersana Therapeutics (NASDAQ:MRSN)August 5 at 2:41 AM | americanbankingnews.comChemomab Therapeutics Enters Sales Agreement with LifeSci CapitalJuly 28, 2025 | theglobeandmail.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. | Crypto 101 Media (Ad)Chemomab Therapeutics Announces Positive Phase 2 SPRING Trial Results for Nebokitug as Promising Treatment for Primary Sclerosing Cholangitis at BSG Live’25 - NasdaqJuly 2, 2025 | nasdaq.comChemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25July 1, 2025 | finance.yahoo.comChemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25June 30, 2025 | globenewswire.comAnalysts Conflicted on These Healthcare Names: Pfizer (PFE) and Chemomab Therapeutics (CMMB)June 14, 2025 | theglobeandmail.comChemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing CholangitisJune 11, 2025 | globenewswire.comSee More Headlines CMMB Stock Analysis - Frequently Asked Questions How have CMMB shares performed this year? Chemomab Therapeutics' stock was trading at $1.81 at the start of the year. Since then, CMMB stock has decreased by 45.9% and is now trading at $0.98. How were Chemomab Therapeutics' earnings last quarter? Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.06. How do I buy shares of Chemomab Therapeutics? Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Chemomab Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chemomab Therapeutics investors own include Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW), NVIDIA (NVDA), Meta Platforms (META) and Adobe (ADBE). Company Calendar Last Earnings5/15/2025Today8/06/2025Next Earnings (Estimated)8/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMMB CIK1534248 Webwww.chemomab.com Phone972-77-331-0156FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Chemomab Therapeutics$8.50 High Price Target$10.00 Low Price Target$7.00 Potential Upside/Downside+767.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.94 million Net MarginsN/A Pretax MarginN/A Return on Equity-106.70% Return on Assets-82.18% Debt Debt-to-Equity RatioN/A Current Ratio5.33 Quick Ratio5.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book1.36Miscellaneous Outstanding Shares18,860,000Free Float16,611,000Market Cap$18.48 million OptionableNot Optionable Beta0.52 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:CMMB) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.